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A B S T R A C T
Objective: We previously described symptom-based chronic fatigue syndrome (CFS/ME) phenotypes in clinical
assessment data from 7041 UK and 1392 Dutch adult CFS/ME patients. Here we aim to replicate these phe-
notypes in a more recent UK patient cohort, and investigate whether phenotypes are associated with 1-year
treatment outcome.
Methods: 12 specialist CFS/ME services (11 UK, 1 NL) recorded the presence/absence of 5 symptoms (muscle
pain, joint pain, headache, sore throat, and painful lymph nodes) which can occur in addition to the 3 symptoms
(post-exertional malaise, cognitive dysfunction, and disturbed/unrefreshing sleep) that are present for almost all
patients. Latent Class Analysis (LCA) was used to assign symptom proﬁles (phenotypes). Multinomial logistic
regression models were ﬁtted to quantify associations between phenotypes and overall change in health 1 year
after the start of treatment.
Results: Baseline data were available for N = 918 UK and N = 1392 Dutch patients, of whom 416 (45.3%) and
912 (65.5%) had 1-year follow-up data, respectively. 3- and 4-class phenotypes identiﬁed in the previous UK
patient cohort were replicated in the new UK cohort. UK patients who presented with ‘polysymptomatic’ and
‘pain-only’ phenotypes were 57% and 67% less likely (multinomial odds ratio (MOR) 0.43 (95% CI 0.19-0.94)
and 0.33 (95% CI 0.13-0.84)) to report that their health was “very much better” or “much better” than patients
who presented with an ‘oligosymptomatic’ phenotype. For Dutch patients, polysymptomatic and pain-only
phenotypes were associated with 72% and 55% lower odds of improvement (MOR 0.28 (95% CI 0.11, 0.69) and
0.45 (95% CI 0.21, 0.99)) compared with oligosymptomatic patients.
Conclusions: Adult CFS/ME patients with multiple symptoms or pain symptoms who present for specialist
treatment are much less likely to report favourable treatment outcomes than patients who present with few
symptoms.
1. Introduction
Chronic fatigue syndrome (CFS), also known as myalgic en-
cephalomyelitis (ME) or, more recently in the USA, systemic exertion
intolerance disease (SEID) [1], is deﬁned as persistent or recurrent
debilitating fatigue that is not lifelong, or the result of ongoing exertion,
or alleviated by rest, or explained by other conditions, and that results
in a substantial reduction in activity [2,3]. A meta-analysis of studies
based on clinically-conﬁrmed cases in several countries indicated a
prevalence of 0.76% (95% CI 0.23% to 1.29%) [4]. CFS/ME imposes a
huge burden on patients, careers and families [5,6]. In the UK, adults
who attend NHS specialist CFS/ME services have been ill for a median
duration of 3 years, and half of those employed at the onset of their
illness have ceased working [7].
In a previous study, we used latent class analysis to identify CFS/ME
‘phenotypes’ based on symptoms in CFS/ME patients attending UK
specialist CFS/ME services from 2010 to 2013 [8]. Post-exertional
malaise, cognitive dysfunction and disturbed/unrefreshing sleep were
near universal symptoms. The other 5 symptoms (muscle pain, joint
pain, headache, sore throat, and painful lymph nodes) delineated 3
phenotypes, characterized as ‘polysymptomatic’, ‘oligosymptomatic’,
and ‘pain-only’ [8]. We replicated these 3 phenotypes in a cohort of
CFS/ME patients attending a Dutch specialist CFS/ME service and, in
both cohorts, the phenotypes were strongly associated with patient-
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reported measures of illness severity and with comorbidities.
The two aims of the present study were: 1) to replicate the original
symptom-based CFS/ME phenotypes in a new UK cohort of CFS/ME
patients; and 2) to investigate whether phenotypes were related to
patient-reported treatment outcomes in the new UK cohort and in the
original Dutch patient cohort.
2. Methods
2.1. UK CFS/ME patient cohort
Patients were recruited from 11 specialist CFS/ME services across
England (10 NHS services, 1 registered independent provider) during
the period 01/06/2014 to 30/09/2016. Patients were eligible if they
were≥18 years old and had a CFS/ME diagnosis made or conﬁrmed at
an initial clinical assessment appointment in accordance with NICE
guidelines [2]. Patients were assessed and treated by clinicians and
therapists who have specialist training and experience in the diagnosis
and treatment of CFS/ME. The assessment included recording the pre-
sence/absence of 12 pre-speciﬁed symptoms, under guidance that the
symptom should have persisted/recurred during ≥4 consecutive
months, did not predate the fatigue and was not caused by some other
medical condition. The 12 symptoms were: sleep disturbance/un-
refreshing sleep; joint pain; muscle pain; headaches; painful lymph
nodes; sore throat; cognitive dysfunction; post-exertional malaise;
general malaise/ﬂu-like symptoms; dizziness; nausea; palpitations.
Clinicians also recorded the presence/absence of common comorbid-
ities, including migraine, Irritable Bowel Syndrome (IBS), Fi-
bromyalgia, depression, and anxiety. At the time of their initial as-
sessment, patients completed standard questionnaires to obtain
quantitative measures of fatigue (Chalder Fatigue Scale [9] and
Checklist Individual Strength (CIS20-R) [10]) and physical function
(RAND SF-36 [11]). Approximately 12 months after their initial clinical
assessment, patients were asked to rate changes in their overall health
on a Clinical Global Impression scale. They were asked “Overall, how
much do you feel your health has changed since you ﬁrst came to the
CFS/ME service?”with possible responses of “very much”, “much” or “a
little” better, “no change”, or “very much”, “much” or “a little” worse.
Patients who didn't respond were contacted by the clinical team via
phone or email on up to 2 further occasions to elicit a response. Out-
comes were coded as ‘Much better’ (=“Very much better” or “Much
better”), ‘Worse’ (=“Very much worse” or “Much worse”) or ‘Un-
changed’ (=“A little better”, “No change” or “A little worse”).
2.2. Dutch CFS/ME patient cohort
The Dutch cohort comprised adults diagnosed with CFS/ME and
treated at a tertiary specialist care centre during the period 2007–2012
in accordance with Centers for Disease Control and Prevention (CDC)
criteria [3,12] and Dutch guidelines [13,14]. A Checklist Individual
Strength (CIS20-R) fatigue subscale score≥ 35 [10] and a Sickness
Impact Proﬁle (SIP) score≥ 700 were used as operational criteria for
fatigue that was severe enough to cause substantial functional impair-
ment [15]. Consultants in the outpatient clinic of the Department of
Internal Medicine assessed the medical status of all patients, and
decided whether patients had been suﬃciently evaluated to rule out an
alternative explanation for their fatigue. Patients were given a full
physical examination (unless this had already been completed), case
history evaluation and laboratory tests. CDC diagnostic criteria include
a set of 8 persistent/recurrent symptoms occurring during 6 or more
consecutive months: unrefreshing sleep; pain in several joints; muscle
pain; headache; tender lymph nodes; sore throat; impaired memory;
impaired concentration; and feeling ill after exertion. Patients were
asked “Which of the following complaints did you experience during
the last 6 months?” and, if aﬃrmative, whether the symptom had been
experienced for “less than” or “longer than” 6 months. We coded
responses of “Not at all” and “Sometimes (each month)” as ‘symptom
absent’ and responses of “Sometimes (each week)” and “Daily” as
‘symptom present’. The latter also required the symptom to have been
experienced for “longer than” 6 months. ‘Post-exertional malaise’ was
in response to a question asking whether symptoms were worse after
physical eﬀort; ‘Cognitive dysfunction’ was based on an aﬃrmative
response to one or both of two separate questions about forgetfulness
and concentration; ‘Sleep disturbance’ was in response to a question
asking whether the patient woke up unrefreshed. Responses were re-
corded by self-completed questionnaire. Patients completed the CIS20-
R after 12 months' follow up. Patients were classiﬁed as ‘Much better’ if
their 12-month follow-up CIS20-R fatigue and SF-36 physical function
subscale scores were ‘normal’ (< 35 and≥65, respectively) [15] and if
their fatigue had decreased by ≥8 points (corresponding to
1.96 × Reliable Change Index (RCI), where RCI = √2 × SDhealthy po-
pulation × √(1− Cronbach α) [16]. For the CSI20-R fatigue subscale,
α= 0.93 and SDhealthy population = 10.75 [17]. Patients' health was
classiﬁed as ‘Worse’ if their fatigue score had increased, and all other
patients were classiﬁed as ‘Unchanged’.
2.3. Ethical approvals
The UK study had NHS Research Ethics Committee approval (14/
NW/0242), and all patients provided written informed consent. The
medical-ethical committee of the Radboud University Nijmegen
Medical Centre ruled that the collection and analysis of Dutch CFS/ME
patient data did not require ethical review. Dutch CFS/ME patient data
were collected as part of routine clinical practice.
2.4. Statistical methods
2.4.1. CFS/ME phenotypes
CFS/ME phenotypes in the UK patient cohort were explored using
the same method as described in our earlier study [8]. Post-exertional
malaise, cognitive dysfunction and disturbed/unrefreshing sleep were
near universal symptoms, therefore we based our analysis on the ﬁve
other symptoms recorded in both cohorts, namely: muscle pain, joint
pain, headache, sore throat, and painful lymph nodes (dizziness,
nausea, and palpitations were recorded only in the UK cohort). We used
latent class analysis (LCA) to identify subtypes of related cases (latent
classes, or ‘phenotypes’) according to presence/absence of each
symptom [18]. Patients are ‘assigned’ (probabilistically) to one of a pre-
deﬁned number of discrete latent classes based on the presence or ab-
sence of symptoms. The optimum class solution, i.e. the optimum
number of classes, is selected by inspection and comparison of various
model ﬁt statistics [19], including: 1) Bayesian Information Criterion
(BIC); 2) bivariate model ﬁt - a test of the conditional independence
assumption (within each class, there should be no association of one
symptom with another, because all associations between symptoms are
accounted for by class membership); 3) entropy - a measure of how well
individuals have been classiﬁed (based on class membership prob-
abilities) - a value of ‘1’ indicates perfect separation of the classes; 4)
Lo-Mendell-Rubin adjusted likelihood ratio test for c compared with c-1
classes; and 5) bootstrapped likelihood ratio test (BLRT) for c compared
with c-1 classes. Selection of the optimum latent class solution, parti-
cularly when the statistical selection criteria are inconclusive, may also
be informed by subjective input, including: clinical/biological plausi-
bility, prior knowledge of likely heterogeneity within CFS/ME, and the
clinical and epidemiological utility of any solution. The probabilities of
reporting each symptom across the latent classes obtained from the
original and new UK patient datasets were compared by visual in-
spection.
2.4.2. Associations of CFS/ME phenotypes with patient-reported outcome
Multinomial odds ratios (MORs) adjusted for age and sex were es-
timated using multinomial logistic regression with a 3-level ordinal
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outcome variable (‘Much better’, ‘Unchanged’ (reference), or ‘Worse’).
We used an implementation in Mplus version 7.11 (Muthén and
Muthén, 2013) of the 3-step method proposed by Jeroen Vermunt
[20,21]. Models were derived initially using the normative latent class
as the baseline category for the outcome. The models were then re-
parameterized to investigate possible diﬀerences between the classes,
using each class in turn as reference class. This method has been shown
to produce less biased estimates than traditional 3-step methods, such
as probability weighting and modal class assignment, whilst avoiding
the problem of covariates impacting on the measurement model itself
[20]. To investigate whether our symptom-based phenotypes were as-
sociated with outcomes at 1 year independently of severity of illness,
we further adjusted our MORs for baseline fatigue and physical func-
tion. Mean values of baseline fatigue and physical function across the
latent classes and associations of sex, age group and comorbidities with
latent classes were estimated using the same 3-step approach.
3. Results
3.1. UK and Dutch patient characteristics
Baseline data were available for 918 UK and 1392 Dutch patients.
Demographic characteristics of UK and Dutch patients were broadly
similar (Table 1), although the Dutch cohort was slightly younger
(median 37 (IQR 27–46)) years compared to 41 (30–50) years
(p = 0 < 0.001) and had a slightly higher proportion of men (25.6%
(356/1036) compared to 19.0% (174/918), p < 0.001). Dutch pa-
tients had higher SF36 physical function scores (median 55 (40–70)
compared to 40 (25–60), p < 0.001, high score = less disabled). 12-
month follow-up data were available for 416 (45.3%) UK and 912
(65.5%) NL patients. UK patients lost to follow-up were slightly
younger than those who had follow-up data (mean 39.6 vs 42.1 years,
p = 0.005) but there were no diﬀerences in sex or baseline fatigue and
physical function. Dutch patients lost to follow-up were slightly older
than those who had follow-up data (mean 38.2 vs 36.7 years,
p = 0.02), were more likely to be male (28.8% vs 23.9%) and had
worse baseline physical function (mean 54.0 vs 58.4, p < 0.001) but
there was no diﬀerence in baseline fatigue. Overall changes in health
were broadly similar in the two cohorts: 27.6% of UK patients reported
their health to be very much or much better, 63.5% reported little or no
change, and 8.9% said that their health was worse, compared with
59.8%, 33.0%, and 7.2% of Dutch patients classiﬁed (by fatigue and
physical function score) as much better, unchanged or worse, respec-
tively (p < 0.001).
3.2. CFS/ME phenotypes in UK patient cohort
The 3- and 4-class solutions previously identiﬁed in Dutch and UK
patient cohorts were replicated in the new UK patient cohort (Figs. 1 &
2, Table S1). As before, classes in the 3-class solution represented
‘polysymptomatic’, ‘pain only’, and ‘oligosymptomatic’ phenotypes, and
the 4-class solution delineated an additional ‘sore throat/painful lymph
node/headache’ phenotype. The proportions of patients assigned to
each of the classes in the 3-class solution were similar in the new vs
original UK patient cohorts: ‘polysymptomatic’ 53.4% vs 53.2%; ‘pain-
only’ 32.7% vs 37.6%; and ‘oligosymptomatic’ 13.9% vs % 9.2%
(Fig. 1). There were greater diﬀerences in the distribution of patients
across the 4-class solution in the new vs original UK patient cohorts:
17.9% vs 8.2% ‘oligosymptomatic’; 16.4% vs 10.2% ‘sore throat/
painful lymph node/headache’; and 25.7% vs 36.6% ‘pain-only’
(Fig. 2). No associations between sex and phenotype were evident
(Table S2). Dutch patients 40–59 years old were much more likely to a
pain or polysymptomatic phenotype, compared with patients age
18–29 years (Table S2). No associations between age and phenotype
were evident for UK patients. In both cohorts, baseline fatigue and
physical function were indicative of more severe illness in pain and
polysymptomatic cf. oligosymptomatic patients (Table S2).
Patients presenting with a polysymptomatic phenotype were more
likely to have comorbid migraine, IBS, depression, and anxiety com-
pared to oligosymptomatic patients (Table S2). Fibromyalgia as a co-
morbidity was reported for 36% and 24% of patients classiﬁed with
pain and polysymptomatic phenotypes, respectively; too few oligo-
symptomatic patients (3%) had comorbid ﬁbromyalgia to allow esti-
mation of odds ratios using this phenotype as the reference group.
3.3. Associations of CFS/ME phenotypes with treatment outcomes
Using the 3-class solution, UK and Dutch patients presenting with
polysymptomatic and pain only phenotypes were much less likely to
report substantial improvement in their health at 12 months, compared
to patients presenting with the oligosymptomatic phenotype (Table 2).
Adjusted multinomial odds ratios (MOR) showed that, compared with
oligosymptomatic patients, UK patients who were polysymptomatic
were 58% less likely to report their health as being ‘much better’
(MOR = 0.42 (95% CI 0.20, 0.89)) and patients with predominantly
pain-only symptoms were 65% less likely (MOR = 0.35 (0.15, 0.82)) to
report substantial improvement. Similar eﬀects were seen in poly-
symptomatic and pain-only Dutch patients, who were respectively 51%
(MOR = 0.49 (0.31, 0.80)) and 42% (MOR = 0.58 (0.39, 0.88)) less
likely to be classiﬁed as being much better. There were no associations
between phenotypes and substantially worse health, although estimates
were imprecise because of the relatively small numbers of patients
whose health had deteriorated. Further adjustment of the MORs for
baseline fatigue and physical function changed the UK estimates
slightly, the Dutch estimates to a greater degree (towards bigger ef-
fects), but the overall pattern of eﬀects was unchanged and evidence
remained for inverse associations of polysymptomatic and pain only
phenotypes with much improved health (Table 2).
4. Discussion
Symptom-based CFS/ME phenotypes that we identiﬁed in a
Table 1








Median (IQR) or n
(%)
Age (years) 41 (30–50) 37 (27–46) p < 0.001
Sex (female) 744 (81.1%) 1036 (74.4%) p < 0.001
Symptoms
Muscle pain 766 (83.4%) 948 (68.1%) p < 0.001
Joint pain 644 (70.2%) 808 (58.1%) p < 0.001
Headaches 605 (65.9%) 760 (54.6%) p < 0.001
Painful lymph nodes 402 (43.8%) 309 (22.2%) p < 0.001
Sore throat 497 (54.1%) 251 (18.0%) p < 0.001
CIS20-R fatigue score
(range 8–56)
50 (46–53) 51 (47–55) p < 0.001
SF-36 physical function
(range 0–100)
40 (25–60) 55 (40–70) p < 0.001
Follow-up at 1 year 416 (45.3%) 912 (65.5%) p < 0.001
Overall improvement at
1 yearb
Unchanged 264 (63.5%) 301 (33.0%) p < 0.001
Much better 115 (27.6%) 545 (59.8%)
Worse 37 (8.9%) 66 (7.2%)
a Kruskal-Wallis test for medians, Chi-squared test for proportions.
b In UK patients, Clinical Global Impression scale, where ‘Much better’ = “Very much
better” or “Much better”, ‘Worse’ = “Very much worse” or “Much worse” or
‘Unchanged’ = “A little better”, “No change” or “A little worse”; in Dutch patients,
change in CIS20-R fatigue score, where ‘Much better’ = score < 35 and change> 7 and
SF-36 score ≥ 65, ‘Worse’ = change< 0, ‘Unchanged’ = all other responses.
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previous UK clinical cohort of adult CFS/ME patients were replicated in
a new UK cohort of patients. These phenotypes were associated with
treatment outcomes, in that patients who presented with multiple
symptoms (in addition to post-exertional malaise, cognitive dysfunction
and disturbed/unrefreshing sleep) or with pain as additional symptoms
were much less likely to experience a substantial improvement in their
health one year after the start of treatment. These associations were
similar in UK and Dutch patients, and were robust to adjustment for
severity of illness at initial clinical assessment (most notably, a higher
level of physical function in Dutch patients).
The main strengths of our study lie in the large sample sizes of our
patient cohorts, and that all patients were diagnosed at specialist CFS/
ME services in either secondary (UK) or tertiary (NL) specialist CFS/ME
facilities. The main limitations of our study are that improvement in
health one year after treatment was measured diﬀerently in UK and
Dutch patients, and the UK cohort had high losses to follow up. For UK
patients, we relied on patients' self-reported impression of their overall
improvement in health, and for Dutch patients we calculated a reliable
change index. The aim of our study was to investigate whether phe-
notypes were associated with patient-reported treatment outcomes,
rather than to quantify precisely any such associations. This means that
the magnitude of the observed eﬀects should be interpreted cautiously,
and our results should instead be interpreted in terms of the consistency
of eﬀects across the two cohorts - namely, that patients with ‘poly-
symptomatic’ and ‘pain-only’ phenotypes were much less likely to
beneﬁt from specialist treatment in either the UK or the Netherlands.
This consistency was observed despite between-cohort diﬀerences in
diagnostic criteria and patient characteristics. Treatment outcome in
Fig. 1. 3-class solution based on 5 symptoms in UK adult CFS/ME patient cohorts.
Fig. 2. 4-class solution based on 5 symptoms in UK adult CFS/ME patient cohorts.
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the UK cohort may have been biased by diﬀerential losses to follow up,
but phenotype was not associated with loss to follow up, and we have
no reason to suspect that the association between phenotype and out-
come was biased. The generalizability of our ﬁndings is limited in that
the two cohorts comprised people who had access to specialist services,
representing an unknown proportion of all potential patients. Our ori-
ginal study in UK patients found a 6-class solution based on nine
symptoms (the ﬁve in the present study, plus dizziness, nausea, and
palpitations) [8]. The 3-class solution in the present study arose be-
cause we wanted to compare associations of phenotypes with treatment
outcomes between the UK and Dutch cohorts. The small number of
symptoms common to both cohorts, and the smaller size of these co-
horts relative to the original UK cohort, precluded replication of the 6-
class solution. The simpler 3-class solution shares key features with the
6-class solution, namely the poorer baseline health status and more
likely occurrence of comorbidities among polysymptomatic patients.
Our outcomes were deﬁned to diﬀerentiate patients who had im-
proved, rather than attempting to deﬁne ‘recovery’, which is a complex
(and controversial) topic in CFS/ME [22–24]. Treatment eﬀects at the
Dutch specialist service in our study were better than a comparable UK
specialist service (not involved in our study), a diﬀerence which per-
sisted after adjusting for baseline characteristics [25]. The higher pro-
portion of Dutch vs UK patients who were classiﬁed as ‘much better’ in
our study (59.8% vs 27.6%) may be a true diﬀerence in treatment
outcomes (we did not have data to compare the intensity and duration
of treatments received), or a consequence of the diﬀerent deﬁnitions of
improvement, or because Dutch patients had levels of physical function
commensurate with less severe illness at baseline, or a combination of
all three.
Although many patients derive substantial beneﬁt from treatments
provided by specialist services, there remain in both countries groups of
patients who do not improve, and a small group whose condition is
worse at follow up [26,27]. Our ﬁndings show that patients with dif-
ferent phenotypes have diﬀerent prognoses. From a CFS/ME specialist
service perspective, this might suggest the importance of individualised
treatment, for example, for patients with pain symptoms, who have less
favourable treatment outcomes [28–30]. However, from a broader
healthcare perspective, it could be argued that a more comprehensive
framework of clinical management of patients with symptom-based
diagnoses/functional somatic symptoms is needed [31,32]. From this
perspective, the setting of our study within the boundaries of specialist
CFS/ME services (well established in the UK and the Netherlands, much
less so in most other countries) could be perceived as a limitation.
Whether multiple symptoms and functional somatic symptoms de-
lineate subtypes of CFS/ME [33–35], whether CFS/ME is a subtype of
an umbrella syndrome [36], or whether distinct syndromes such as
CFS/ME and ﬁbromyalgia simply occur comorbidly [37] remains an
open question. The answer has major implications for clinical research
and practice, including the design of clinical trials [38] and the role of
illness severity rather than symptomatology in predicting treatment
outcomes [39].
5. Conclusion
The total number of symptoms and the presence of pain symptoms
(in addition to the cardinal symptoms of CFS/ME, namely post-exer-
tional malaise, cognitive dysfunction and disturbed/unrefreshing sleep)
are important predictors of treatment outcome in adult CFS/ME pa-
tients.
Supplementary data to this article can be found online at https://
doi.org/10.1016/j.jpsychores.2017.11.007.
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Table 2
Overall change in health in UK and Dutch adult CFS/ME patients according to symptom-based phenotype (latent class).
UK adult CFS/ME patients Dutch adult CFS/ME patients
Class 1 (15.5%) Class 2 (35.5%) Class 3 (49.0%) Class 1 (22.6%) Class 2 (51.9%) Class 3 (25.4%)





(Reference) Multinomial odds ratio
(95% CI)a




Reference 0.35 (0.15, 0.82) 0.42 (0.20, 0.89) Reference 0.58 (0.39, 0.88) 0.49 (0.31, 0.80)
Worse (cf.
unchanged)















Reference 0.33 (0.13, 0.84) 0.43 (0.19, 0.94) 0.45 (0.21, 0.99) 0.28 (0.11, 0.69)
Worse (cf.
unchanged)
Reference 1.33 (0.27, 6.46) 0.50 (0.10, 2.48) 0.83 (0.52, 1.31) 0.88 (0.52, 1.49)
a Adjusted for age and sex.
b Adjusted for age, sex and baseline fatigue and physical function (UK patients - Chalder Fatigue Scale, SF-36 physical function subscale; Dutch patients - CIS20-R fatigue subscale, SF-
36 physical function subscale).
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